Comparison Overview

Chiesi USA, Inc.

VS

Glenmark Pharmaceuticals

Chiesi USA, Inc.

175 Regency Woods Place, Ste 600, Cary, North Carolina, US, 27518
Last Update: 2025-12-22
Between 650 and 699

Chiesi USA, Inc., headquartered in Cary, N.C., is a specialty pharmaceutical company focused on commercialization of products for the hospital, rare disease and target office-based specialties. Our employees take an entrepreneurial approach to meet the evolving needs of our customers. As a Public Benefit Corporation, Chiesi USA is committed to operating as a good corporate citizen; positively impacting communities in which we live and serve. Headquartered in Cary NC, we employ over 360 employees in the United States. Previously known as Cornerstone Therapeutics, the company was acquired by the Chiesi Group in 2014. Chiesi USA, Inc. is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. Headquartered in Parma, Italy, Chiesi Farmaceutici is an international research-focused group with more than 80 years of experience in the pharmaceutical industry. The Group employs more than 5,300 people in 27 affiliates worldwide, selling products in more than 80 countries. Chiesi is recognized as a top 50 company in terms of revenue and R&D. Careers at Chiesi USA Inc: Email: [email protected] Business Development: Email: [email protected] All other inquiries: Email: [email protected]

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 532
Subsidiaries: 2
12-month incidents
1
Known data breaches
1
Attack type number
1

Glenmark Pharmaceuticals

Glenmark House, B.D.Sawant Marg,, Chakala, Andheri (East), Mumbai, Maharashtra, IN, 400099
Last Update: 2025-12-17

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,411
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/chiesi-usa.jpeg
Chiesi USA, Inc.
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/glenmark-pharmaceuticals.jpeg
Glenmark Pharmaceuticals
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Chiesi USA, Inc.
100%
Compliance Rate
0/4 Standards Verified
Glenmark Pharmaceuticals
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

Chiesi USA, Inc. has 8.7% more incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Glenmark Pharmaceuticals in 2025.

Incident History — Chiesi USA, Inc. (X = Date, Y = Severity)

Chiesi USA, Inc. cyber incidents detection timeline including parent company and subsidiaries

Incident History — Glenmark Pharmaceuticals (X = Date, Y = Severity)

Glenmark Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/chiesi-usa.jpeg
Chiesi USA, Inc.
Incidents

Date Detected: 12/2025
Type:Breach
Blog: Blog
https://images.rankiteo.com/companyimages/glenmark-pharmaceuticals.jpeg
Glenmark Pharmaceuticals
Incidents

No Incident

FAQ

Glenmark Pharmaceuticals company demonstrates a stronger AI Cybersecurity Score compared to Chiesi USA, Inc. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Chiesi USA, Inc. company has historically faced a number of disclosed cyber incidents, whereas Glenmark Pharmaceuticals company has not reported any.

In the current year, Chiesi USA, Inc. company has reported more cyber incidents than Glenmark Pharmaceuticals company.

Neither Glenmark Pharmaceuticals company nor Chiesi USA, Inc. company has reported experiencing a ransomware attack publicly.

Chiesi USA, Inc. company has disclosed at least one data breach, while the other Glenmark Pharmaceuticals company has not reported such incidents publicly.

Neither Glenmark Pharmaceuticals company nor Chiesi USA, Inc. company has reported experiencing targeted cyberattacks publicly.

Neither Chiesi USA, Inc. company nor Glenmark Pharmaceuticals company has reported experiencing or disclosing vulnerabilities publicly.

Neither Chiesi USA, Inc. nor Glenmark Pharmaceuticals holds any compliance certifications.

Neither company holds any compliance certifications.

Chiesi USA, Inc. company has more subsidiaries worldwide compared to Glenmark Pharmaceuticals company.

Glenmark Pharmaceuticals company employs more people globally than Chiesi USA, Inc. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Chiesi USA, Inc. nor Glenmark Pharmaceuticals holds SOC 2 Type 1 certification.

Neither Chiesi USA, Inc. nor Glenmark Pharmaceuticals holds SOC 2 Type 2 certification.

Neither Chiesi USA, Inc. nor Glenmark Pharmaceuticals holds ISO 27001 certification.

Neither Chiesi USA, Inc. nor Glenmark Pharmaceuticals holds PCI DSS certification.

Neither Chiesi USA, Inc. nor Glenmark Pharmaceuticals holds HIPAA certification.

Neither Chiesi USA, Inc. nor Glenmark Pharmaceuticals holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A vulnerability has been found in SeaCMS up to 13.3. The affected element is an unknown function of the file js/player/dmplayer/dmku/class/mysqli.class.php. Such manipulation of the argument page/limit leads to sql injection. The attack can be executed remotely. The exploit has been disclosed to the public and may be used.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in HappyDevs TempTool allows Stored XSS.This issue affects TempTool: from n/a through 1.3.1.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in Tormorten WP Microdata allows Stored XSS.This issue affects WP Microdata: from n/a through 1.0.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
Description

Exposure of Sensitive System Information to an Unauthorized Control Sphere vulnerability in HappyDevs TempTool allows Retrieve Embedded Sensitive Data.This issue affects TempTool: from n/a through 1.3.1.

Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
Description

A vulnerability has been found in Tenda FH1201 1.2.0.14(408). Affected is the function sprintf of the file /goform/SetIpBind. Such manipulation of the argument page leads to stack-based buffer overflow. The attack may be performed from remote. The exploit has been disclosed to the public and may be used.

Risk Information
cvss2
Base: 9.0
Severity: LOW
AV:N/AC:L/Au:S/C:C/I:C/A:C
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
cvss4
Base: 7.4
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X